APPLICATION OF OPIOID RECEPTOR ANTAGONISTS WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC SIGNS

• 1. 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 [P] . 中国专利： CN105828821B . 2019.04.09
• 2. 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 [P] . 中国专利： CN105828821A . 2016-08-03
• 3. USE OF OPIOID RECEPTOR ANTAGONIST WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES [P] . 俄罗斯专利： RU2679661C1 . 2019-02-12

  机译： 具有K活性和伏立西汀的阿片受体拮抗剂在治疗忧郁性抑郁症中的应用

• 4. USE OF AN OPIOID RECEPTOR ANTAGONIST WITH KAPPA-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES. [P] . MX368870B . 2019-10-21

  机译： 具有卡帕活性的阿片受体拮抗剂和伏立西汀在治疗忧郁性抑郁症中的应用。

• 5. Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features [P] . AU2014368548B2 . 2019-09-19

  机译： 具有κ活性和伏替西汀的阿片受体拮抗剂在治疗具有忧郁特征的抑郁症中的用途

• 1. Kappa opioid receptor antagonist and N-methyl-D- aspartate receptor antagonist affect dynorphin- induced spinal cord electrophysiologic impairment [J] . Yu Chen, Liangbi Xiang, Jun Liu, 中国神经再生研究（英文版） . 2012,第007期
• 2. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. [J] . Garriock HA, Tanowitz M, Kraft JB, American journal of psychiatry . 2010,第5期
• 3. The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: Results from 4 randomized, double-blind, placebo-controlled studies [J] . GriebelG., BeeskéS., StahlS.M. The journal of clinical psychiatry . 2012,第11期
• 4. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. [J] . Papakostas GI, Fava M European psychiatry: the journal of the Association of European Psychiatrists . 2007,第7期
• 5. Identification of opioid receptor ligand interactions using structurally related delta-opioid receptor agonists and antagonists and molecular modeling. [C] . Sharon D.Bryant, Yunden Jinsmaa, Lawrence H.Lazarus International Peptide Symposium;European Peptide Symposium . 2005
• 6. Using Early Changes in Cognition to Predict Response to 8-week Vortioxetine Treatment in Patients with Major Depressive Disorder [D] . Park, Caroline. 2019
• 7. Major Depressive Disorder and Kappa Opioid Receptor Antagonists [O] . Wei Li, Huijiao Sun, Hao Chen, -1
• 8. Novel 1HPyrrolo3,2cquinoline Based 5HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimers Disease [O] . -1

• 1. Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J] . Masoud Behzadifar ,Hamidreza Dehghan ,Korush Saki . 药理与制药（英文） . 2015,第4期
• 2. Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis [J] . Masoud Behzadifar ,Abouzar Keshavarzi ,Abed Tofighian . 行为与脑科学期刊（英文） . 2015,第10期
• 3. Nuclear receptors modulate inflammasomes in the pathophysiology and treatment of major depressive disorder [J] . Han Wang ,Wei-Jing Kan ,Yuan Feng . 世界精神病学杂志 . 2021,第12期
• 4. Levomilnacipran and vortioxetine： Review of new pharmacotherapies for major depressive disorder [J] . Mei T Liu ,Megan E Maroney ,Evelyn R Hermes-DeSantis . 世界药理学杂志 . 2015,第001期
• 5. 度洛西汀与帕罗西汀治疗伴躯体症状抑郁症的对照研究 [C] . 陈进东 ,黄志源 . 第十三届全国中西医结合精神疾病学术会议 . 2014
• 6. 阿戈美拉汀和度洛西汀治疗抑郁症的成本效果分析 [A] . 马含情 . 2016